Author: admin

Progressive Supranuclear Palsy Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Woolsey Pharma, Asahi Kasei Pharma, AlzProtect, Amylyx Pharma, Transposon

The Key Progressive Supranuclear Palsy Companies in the market include – Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma’s, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others.

 

DelveInsight’s “Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Progressive Supranuclear Palsy, historical and forecasted epidemiology as well as the Progressive Supranuclear Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Progressive Supranuclear Palsy, offering comprehensive insights into the Progressive Supranuclear Palsy revenue trends, prevalence, and treatment landscape. The report delves into key Progressive Supranuclear Palsy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Progressive Supranuclear Palsy therapies. Additionally, we cover the landscape of Progressive Supranuclear Palsy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Progressive Supranuclear Palsy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Progressive Supranuclear Palsy space.

 

To Know in detail about the Progressive Supranuclear Palsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Progressive Supranuclear Palsy Market Forecast

 

Some of the key facts of the Progressive Supranuclear Palsy Market Report: 

  • The Progressive Supranuclear Palsy market size was valued ~USD 8.3 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In October 2024, GemVax & KAEL Co., Ltd. (“GemVax”; KOSDAQ ticker: 082270) announced that the topline results from the Phase 2a clinical trial (the “Phase 2a PSP Clinical Trial”) of GV1001, an experimental peptide drug for treating progressive supranuclear palsy (“PSP”), were presented at “Neuro2024.”

  • In September 2024, Ferrer, a B Corp-certified global pharmaceutical company, announced the administration of the first dose in the Phase II clinical trial, PROSPER. The trial aims to assess the safety and efficacy of FNP-223,1, a new therapy designed to slow the progression of Progressive Supranuclear Palsy (PSP).

  • In 2022, the US held the largest market share for PSP, accounting for around 44% of the total PSP market. This is expected to grow significantly during the study period with the introduction of new market players.

  • In 2022, the PSP market size in EU4 and the UK was approximately USD 2.4 million. DelveInsight’s analysis indicates that the market is expected to grow during the study period.

  • In 2022, Germany had the largest market size in EU4 and the UK, with approximately USD 0.6 million, while Spain had the smallest. The market is projected to grow, with Germany expected to maintain the largest share, followed by Italy in 2032.

  • Key Progressive Supranuclear Palsy Companies: Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma’s, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others

  • Key Progressive Supranuclear Palsy Therapies: BRAVYL (fasudil), AZP2006 (ezeprogind), AMX0035, TPN-101/OBP-601 (censavudine), ASN90, GV1001, FNP-223, Davunetide, AMX0035, NBMI, and others

  • The Progressive Supranuclear Palsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Progressive Supranuclear Palsy pipeline products will significantly revolutionize the Progressive Supranuclear Palsy market dynamics.

  • In 2022, the total number of prevalent Progressive Supranuclear Palsy (PSP) cases was estimated to be around 80,706 across the 7MM. 

  • In 2022, Japan had the highest prevalence of Progressive Supranuclear Palsy (PSP), contributing almost 29%, while Spain had the lowest, accounting for about 7% of the total prevalent cases.

  • According to DelveInsight analysis, in 2022, the United States had the highest number of diagnosed prevalent cases, representing approximately 33% of the total cases across the 7MM countries.

  • Among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of PSP, with approximately 1,646 cases, while Spain had the lowest, with around 941 cases in 2022.

  • In 2022, approximately 3,077 males and 2,674 females in the US were diagnosed with PSP.  

 

Progressive Supranuclear Palsy Overview

Progressive supranuclear palsy (PSP) is a rare, degenerative neurological disorder that affects movement, balance, vision, speech, and swallowing. It is caused by the deterioration of cells in the brain, particularly in areas that control these functions, such as the brainstem and basal ganglia. Symptoms of PSP typically include difficulty with balance and walking, eye movement problems (especially looking up or down), stiffness, and slurred speech. PSP progresses over time, and there is currently no cure, though treatment can help manage symptoms. It is often misdiagnosed as Parkinson’s disease due to overlapping symptoms.

 

Get a Free sample for the Progressive Supranuclear Palsy Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market

 

Progressive Supranuclear Palsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Progressive Supranuclear Palsy Epidemiology Segmentation:

The Progressive Supranuclear Palsy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalent Cases of PSP in the 7MM

  • Total Diagnosed Prevalent Cases of PSP in the 7MM

  • Gender-specific Diagnosed Prevalent Cases of PSP in the 7MM

  • Phenotype-specific Diagnosed Prevalent Cases of PSP in the 7MM

  • Comorbidity Associated Cases with PSP in the 7MM

 

Download the report to understand which factors are driving Progressive Supranuclear Palsy epidemiology trends @ Progressive Supranuclear Palsy Epidemiology Forecast

 

Progressive Supranuclear Palsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Supranuclear Palsy market or expected to get launched during the study period. The analysis covers Progressive Supranuclear Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Progressive Supranuclear Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Progressive Supranuclear Palsy Therapies and Key Companies

  • BRAVYL (fasudil): Woolsey Pharmaceutical/Asahi Kasei Pharma

  • AZP2006 (ezeprogind): AlzProtect

  • AMX0035: Amylyx Pharmaceuticals

  • TPN-101/OBP-601 (censavudine): Transposon Therapeutics/Oncolys Biopharma’s

  • ASN90: Ferrer/Asceneuron

  • GV1001: GemVax & Kael

  • FNP-223: Ferrer Internacional S.A.

  • Davunetide: Allon Therapeutics

  • AMX0035: Amylyx Pharmaceuticals

  • NBMI: EmeraMed

 

Discover more about therapies set to grab major Progressive Supranuclear Palsy market share @ Progressive Supranuclear Palsy Treatment Landscape

 

Progressive Supranuclear Palsy Market Strengths

  • The new MDS diagnostic criteria for PSP expands the clinical spectrum of the disease by incorporating conditions suggestive of PSP and a variety of symptomatic PSP phenotypes.  

  • Advocacy and support organizations are dedicated to raising awareness, providing resources, and supporting PSP-affected individuals and families.

  • Improvement in understanding PSP pathogenesis has led to the discovery of potential therapies that target tau protein through various modes of actions

 

Progressive Supranuclear Palsy Market Opportunities

  • The lack of approved therapies provides lucrative opportunities for pharma players to develop disease-modifying therapies and capitalize on the untapped market

  • Increasing research can lead to a deeper understanding of PSP, including its underlying mechanisms, risk factors, and potential therapeutic targets

  • Research focusing on the identification of better imaging and biofluid biomarkers will promote early and accurate diagnosis enrollment of appropriate patients who are likely to show more clear beneficial effects in clinical trials

 

Scope of the Progressive Supranuclear Palsy Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Progressive Supranuclear Palsy Companies: Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma’s, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others

  • Key Progressive Supranuclear Palsy Therapies: BRAVYL (fasudil), AZP2006 (ezeprogind), AMX0035, TPN-101/OBP-601 (censavudine), ASN90, GV1001, FNP-223, Davunetide, AMX0035, NBMI, and others

  • Progressive Supranuclear Palsy Therapeutic Assessment: Progressive Supranuclear Palsy current marketed and Progressive Supranuclear Palsy emerging therapies

  • Progressive Supranuclear Palsy Market Dynamics: Progressive Supranuclear Palsy market drivers and Progressive Supranuclear Palsy market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Progressive Supranuclear Palsy Unmet Needs, KOL’s views, Analyst’s views, Progressive Supranuclear Palsy Market Access and Reimbursement 

 

To know more about Progressive Supranuclear Palsy companies working in the treatment market, visit @ Progressive Supranuclear Palsy Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Progressive Supranuclear Palsy Market Report Introduction

2. Executive Summary for Progressive Supranuclear Palsy

3. SWOT analysis of Progressive Supranuclear Palsy

4. Progressive Supranuclear Palsy Patient Share (%) Overview at a Glance

5. Progressive Supranuclear Palsy Market Overview at a Glance

6. Progressive Supranuclear Palsy Disease Background and Overview

7. Progressive Supranuclear Palsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Progressive Supranuclear Palsy 

9. Progressive Supranuclear Palsy Current Treatment and Medical Practices

10. Progressive Supranuclear Palsy Unmet Needs

11. Progressive Supranuclear Palsy Emerging Therapies

12. Progressive Supranuclear Palsy Market Outlook

13. Country-Wise Progressive Supranuclear Palsy Market Analysis (2019–2032)

14. Progressive Supranuclear Palsy Market Access and Reimbursement of Therapies

15. Progressive Supranuclear Palsy Market Drivers

16. Progressive Supranuclear Palsy Market Barriers

17.  Progressive Supranuclear Palsy Appendix

18. Progressive Supranuclear Palsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Progressive Supranuclear Palsy Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Woolsey Pharma, Asahi Kasei Pharma, AlzProtect, Amylyx Pharma, Transposon

Early Bird Registration Now Open for Summer 2025 North American Jewish Choral Festival

““The Festival is for anyone who wants to celebrate the joy of Jewish music,” says Maestro Matthew Lazar, Festival Founder and Director. “The participants include amateur singers, professionals, cantors, conductors, and lovers of Jewish music of all ages.””
The annual North American Jewish Choral Festival (NAJCF), a one-of-a-kind musical experience, brings hundreds of singers together to enjoy five magical days of a life-changing musical experience. One harmonious choral community is led by world-class conductors creating a melodic tapestry of contemporary, folk, classical, and traditional music. The 2025 event will be held from July 20-24 in Stamford, Connecticut. Registration is now open, with special early bird pricing.

Festival attendees have the unique opportunity to interact with and learn from top experts in Jewish choral music in a supportive setting. There are a variety of uplifting Jewish musical activities, including daily community sings; workshops and seminars on a wide range of topics; and evening concerts featuring guest choirs and outstanding performers. “Being able to connect to this type of music and this type of text is something you can’t get anywhere else,” says NAJCF participant Dor Kaminka, an Israeli-American composer and conductor now residing in Los Angeles, California.

NAJCF provides an environment of fun and excitement as well as a sense of healing, hope, unity and Jewish pride, as participants share a bonding experience and forge new friendships.

“The North American Jewish Choral Festival is my happy place,” says Cantor Mira Davis of New York City. “It’s a community of people who are like-minded, love each other, love Israel and love Jewish music — a place where you can be yourself. The friends I’ve made at NAJCF will last a lifetime.” “The power of singing in harmony with so many wonderful people, especially at this time, keeps me coming back,” adds Jim Perlmutter of Rockville, Maryland.

“Whether you’re a novice or a pro, you’ll leave with new skills, new music and new friends to cherish from this transformative Choral Festival,” concludes Maestro Lazar.

The North American Jewish Choral Festival is a program of Zamir Choral Foundation. For a video highlighting the NAJCF experience click here For more information and to register for NAJCF 2025 visit https://zamirchoralfoundation.org/north-american-jewish-choral-festival/

About Zamir Choral Foundation

The Zamir Choral Foundation, created by Matthew Lazar, promotes choral music as a vehicle to inspire Jewish life, literacy, and community. The Foundation’s programs include the North American Jewish Choral Festival; HaZamir: The International Jewish Teen Choir; the acclaimed Zamir Chorale; Zamir Noded for young adult singers; Zamir Conducting Fellows to train the next generation of Jewish choral conductors; and the HaZamir Preparatory Program for middle school singers. Matthew Lazar, Founder and Director of the Zamir Choral Foundation, is the leading force of the Jewish choral movement in the US. He has worked with Leonard Bernstein, Zubin Mehta, Elie Wiesel, Theodore Bikel, Dr. Ruth Westheimer, and others. The Zamir Choral Foundation is guided by an expansive vision of vibrant Jewish identity across the generational, denominational, and political continuums through the study and performance of Jewish music at the highest level of excellence. 

For more information visit www.zamirchoralfoundation.org

Media Contact
Company Name: CATHY CALLEGARI PUBLIC RELATIONS INC
Contact Person: Liz Ammirato
Email: Send Email
Phone: 914-299-3882
Address:159 Madison Avenue, Apt. 5J
City: New York
State: NY
Country: United States
Website: www.callprinc.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Early Bird Registration Now Open for Summer 2025 North American Jewish Choral Festival

Pioneers Redefining Business Civilization, Creators of Value: IVMCR Completes Brand Upgrade

Today, Jingxiong Zhanzu, the founder of IVMCR, announced the successful completion of a brand upgrade for IVMCR’s core philosophy and its multimedia collaboration platform (Instant Voice, Multimedia, Collaboration and Recording, IVMCR). This upgrade officially introduces a new market-facing image. This milestone marks a significant step forward for the company in its pursuit of innovation and excellence as a “human brand.”

The founder of IVMCR, Jingxiong Zhanzu, is one of the most holistic and socially progressive business advisors among many groundbreaking brands. He proposes IVMCR’s core values—completeness, value, meaning, creation, and relationships — focusing on addressing lifelong purchasing tendencies and the ecological chain of related demands, thereby promoting the healthy development of the business ecosystem. His goal is to transcend traditional commercial boundaries and become a “creator of business systems with social value” and a “new generation of value creators and leaders.”

Jingxiong Zhanzu redefines the connotations and extensions of business with unconventional vision, pushing his unique philosophy towards becoming “the most philosophically profound and commercially valuable figure globally.”

As one of the “most comprehensive and socially beneficial business advisors” in China and abroad, IVMCR’s business model has transcended traditional profit motives and is recognized by a wide user base as a “founder of market value standards.” Its influence has far exceeded the achievements of any single industry.

In product innovation, Jingxiong Zhanzu’s unique profit structure design philosophy is: “To avoid the bullets, you must be closest to the missile.” This means you must eliminate the current profit structures that allow you to earn money and upgrade to new points of value and profit creation. Only then can you compel market speculators to rethink immediate profits, allowing the market to iterate. Only by daring to confront challenges can the market undergo lasting innovation.

Thus, all product designs by Jingxiong Zhanzu must possess sufficient exclusivity, positioning themselves as evaluators and founders of a disdain chain in a non-competitive field. The product landscape should transcend merely creating products; it should focus on redefining the intrinsic value and social significance of products. This has allowed the founder of IVMCR to showcase his product vision publicly, earning him the reputation as “one of the most valuable product creators globally” and “the most exclusive product creator.”

Simultaneously, Jingxiong Zhanzu steps beyond traditional business expressions, integrating modern aesthetics and fashion elements to enhance brand experience and reach, exceeding industrialized and technological norms. In the future, IVMCR, through Jingxiong Zhanzu, will continue to embody the identity of a “giver and representative of the intrinsic value of future fashion carriers,” “a stunning creator leader in the modern market,” and “a representative of modern aesthetic value creators,” actively promoting new forms of business communication and constructing bridges between commerce, fashion, art, and philosophy.

More importantly, Jingxiong Zhanzu is redefining the boundaries of value creation with his unique business wisdom. As a “new generation of value creators and leaders,” he is seen as an “entrepreneur and entrepreneurial entity with long-lasting investment value,” making his business model and philosophy focal points in the capital market.

Moreover, his keen business acumen is complemented by a deep insight into the direction of human societal development. Jingxiong Zhanzu’s commitment to being “the best among humanity” signals the birth of a “human brand,” expressing his determination to transcend business cycles and infusing his life’s will and effort into surpassing industry and cyclical definitions, becoming a human brand representative of human development.

This grand narrative about value, meaning, innovation, and human progress shows that in this uncertain era, Jingxiong Zhanzu is proving through action that true commercial value derives not only from profit but from a profound understanding of and active contribution to human societal development. Let us await how IVMCR founder Jingxiong Zhanzu will continue to write the business legend of this era.

Video Link: https://www.youtube.com/embed/iZ-G7-vpLio?si=h9Bp5dUbQYGXj6cH

Media Contact
Company Name: Lingcai Afterlife (Tianjin) Information Co., Ltd
Contact Person: Jingxiong Zhanzu
Email: Send Email
Country: China
Website: http://www.ivmcr.com/#/

Axillary Hyperhidrosis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight

“Axillary Hyperhidrosis Treatment Market”
Axillary Hyperhidrosis Companies are Botanix Pharmaceuticals, Sound Surgical Technologies, LLC., Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, Persōn & Covey, Stratus Pharmaceuticals, Journey Medical Corporation, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, Viatris, Candesant Biomedical, and others

(Albany, USA) DelveInsight’s “Axillary Hyperhidrosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Axillary Hyperhidrosis, historical and forecasted epidemiology as well as the Axillary Hyperhidrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Axillary Hyperhidrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axillary Hyperhidrosis Market Forecast

 

Some of the key facts of the Axillary Hyperhidrosis Market Report:

  • The Axillary Hyperhidrosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Key Axillary Hyperhidrosis Companies: Botanix Pharmaceuticals, Sound Surgical Technologies, LLC., Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, Persōn & Covey, Stratus Pharmaceuticals, Journey Medical Corporation, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, Viatris, Candesant Biomedical, and others
  • Key Axillary Hyperhidrosis Therapies: Sofpironium Bromide, VASE, Glycopyrronium Bromide, Meditoxin, glycopyrronium Topical Wipesl, and others
  • In January 2024, InMode MD Ltd. offers the InMode Pro System with the Morpheus8 Applicator, a computerized device that produces radio frequency energy utilizing Fractional RF technology. The Morpheus8 Applicator, equipped with a 24-pin tip, is specifically designed for treating primary hyperhidrosis in the underarm area.
  • There are currently too few and insufficient epidemiologic data on hyperhidrosis to establish accurate prevalence or impact estimates. According to DelveInsight analysts, there were 10,491,560 cases of axillary hyperhidrosis (AH) in the US as a whole
  • Based on the HDSS scale, the degree of axillary hyperhidrosis was assessed. According to DelveInsight, 1,584,618 people had non-severe symptoms and roughly 1,716,670 people had severe symptoms in 2021
  • In the US, there were 3,301,288 diagnosed cases of axillary hyperhidrosis (AH) overall in 2021.
  • The prevalence of primary axillary hyperhidrosis in the population of Japan aged 5-64 years is 5.75% (males, 6.60%; females, 4.72%), according to a study by Murota et al. (2021).
  • The Axillary Hyperhidrosis epidemiology based on gender analyzed that in the US, out of the total diagnosed cases of Axillary Hyperhidrosis in 2021, 93% accounted for primary hyperhidrosis and 7% accounted for secondary hyperhidrosis
  • The Axillary Hyperhidrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Axillary Hyperhidrosis pipeline products will significantly revolutionize the Axillary Hyperhidrosis market dynamics.

 

Axillary Hyperhidrosis Overview

Axillary hyperhidrosis is a condition characterized by excessive sweating in the underarm area, beyond what is necessary for thermoregulation. It is a form of focal hyperhidrosis and typically begins in adolescence or early adulthood. While not life-threatening, the condition can significantly impact quality of life by causing discomfort, social embarrassment, and challenges in daily activities.

The exact cause of axillary hyperhidrosis is not fully understood but is believed to involve overactivity of the eccrine sweat glands, triggered by overstimulation of the sympathetic nervous system. It often occurs without an underlying medical condition but may occasionally be secondary to other disorders like hyperthyroidism or certain medications.

Diagnosis is clinical, based on patient history and physical examination, with additional tests like the iodine-starch test used to assess sweating severity.

Treatment aims to reduce sweating and improve the patient’s quality of life. First-line options include topical antiperspirants containing aluminum chloride and prescription-strength formulations. Botulinum toxin (Botox) injections are highly effective for temporary relief. Other interventions include iontophoresis, microwave thermolysis, or surgical procedures like sympathectomy in severe cases. Emerging treatments, such as lasers and topical neurotoxins, offer promising alternatives.

Lifestyle modifications, including wearing breathable fabrics and avoiding triggers, complement medical interventions in managing axillary hyperhidrosis effectively.

 

Get a Free sample for the Axillary Hyperhidrosis Market Report: Axillary Hyperhidrosis Market Trends

 

Axillary Hyperhidrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Axillary Hyperhidrosis Epidemiology Segmentation:

The Axillary Hyperhidrosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

  • Total Prevalence of Axillary Hyperhidrosis
  • Prevalent Cases of Axillary Hyperhidrosis by severity
  • Gender-specific Prevalence of Axillary Hyperhidrosis
  • Diagnosed Cases of Episodic and Chronic Axillary Hyperhidrosis

 

Download the report to understand which factors are driving Axillary Hyperhidrosis epidemiology trends @ Axillary Hyperhidrosis Epidemiology Forecast

 

Axillary Hyperhidrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axillary Hyperhidrosis market or expected to get launched during the study period. The analysis covers Axillary Hyperhidrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Axillary Hyperhidrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Axillary Hyperhidrosis Therapies and Key Companies

  • Sofpironium bromide (BBI-4000): Botanix Pharma
  • VASER: Sound Surgical Technologies, LLC.
  • Glycopyrronium Bromide: Dr. August Wolff GmbH
  • Meditoxin: Medy-Tox
  • glycopyrronium Topical Wipes: Journey Medical Corporation

 

Discover more about therapies set to grab major Axillary Hyperhidrosis market share @ Axillary Hyperhidrosis Treatment Market

 

Scope of the Axillary Hyperhidrosis Market Report

  • Study Period: 2019-2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Axillary Hyperhidrosis Companies: Botanix Pharmaceuticals, Sound Surgical Technologies, LLC., Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, Persōn & Covey, Stratus Pharmaceuticals, Journey Medical Corporation, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, Viatris, Candesant Biomedical, and others
  • Key Axillary Hyperhidrosis Therapies: Sofpironium Bromide, VASE, Glycopyrronium Bromide, Meditoxin, glycopyrronium Topical Wipes, and others
  • Axillary Hyperhidrosis Therapeutic Assessment: Axillary Hyperhidrosis current marketed and Axillary Hyperhidrosis emerging therapies
  • Axillary Hyperhidrosis Market Dynamics: Axillary Hyperhidrosis market drivers and Axillary Hyperhidrosis market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Axillary Hyperhidrosis Unmet Needs, KOL’s views, Analyst’s views, Axillary Hyperhidrosis Market Access and Reimbursement

 

To know more about Axillary Hyperhidrosis companies working in the treatment market, visit @ Axillary Hyperhidrosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Axillary Hyperhidrosis Market Report Introduction

2. Executive Summary for Axillary Hyperhidrosis

3. SWOT analysis of Axillary Hyperhidrosis

4. Axillary Hyperhidrosis Patient Share (%) Overview at a Glance

5. Axillary Hyperhidrosis Market Overview at a Glance

6. Axillary Hyperhidrosis Disease Background and Overview

7. Axillary Hyperhidrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Axillary Hyperhidrosis

9. Axillary Hyperhidrosis Current Treatment and Medical Practices

10. Axillary Hyperhidrosis Unmet Needs

11. Axillary Hyperhidrosis Emerging Therapies

12. Axillary Hyperhidrosis Market Outlook

13. Country-Wise Axillary Hyperhidrosis Market Analysis (2019-2032)

14. Axillary Hyperhidrosis Market Access and Reimbursement of Therapies

15. Axillary Hyperhidrosis Market Drivers

16. Axillary Hyperhidrosis Market Barriers

17. Axillary Hyperhidrosis Appendix

18. Axillary Hyperhidrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Axillary Hyperhidrosis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight

Top Real Estate Selling Agent in Bozeman, MT Revolutionizes Property Sales with Award-Winning Staging Techniques

Bozeman, MT – Revolutionizing the real estate landscape in Bozeman, Sarah O’Neil, renowned for her innovative staging techniques, has once again set a new standard in property sales. Her unique approach not only enhances the aesthetic appeal of properties but significantly boosts their market value, demonstrating why she recognized as a top real estate agent in Bozeman, MT.

Sarah’s staging services have garnered accolades and recognition, making her a sought-after real estate selling agent in Bozeman, MT. “Staging is more than just preparing a home for sale; it’s about creating an environment that buyers can envision as their own,” Sarah explains. This philosophy has helped countless clients achieve faster sales and better pricing, emphasizing the critical role of staging in today’s real estate market.

Her success is built on a foundation of deep market knowledge and a keen understanding of buyer psychology. As a Realtor in Bozeman, MT, Sarah ensures that every property she represents stands out in the competitive market. Her ability to transform spaces into inviting homes makes her services invaluable to sellers looking to maximize returns on their investments.

Furthermore, Sarah’s reputation as a Realtor agent in Bozeman, MT is bolstered by her commitment to client satisfaction and her extensive network within the real estate community. These connections facilitate smoother transactions and better collaboration among all parties involved in the selling process.

Sarah also places a high value on continuous learning and adapting to new trends, which helps her maintain her edge in the staging field. Her innovative techniques are influenced by the latest design trends and market demands, ensuring that each staged home meets the highest standards of contemporary aesthetics and buyer appeal.

Clients frequently attribute their swift and profitable sales to Sarah’s meticulous attention to detail and her visionary staging skills. Her approach not only enhances the visual appeal of a property but also strategically highlights its best features, enticing potential buyers the moment they step through the door.

For those interested in selling their home or purchasing a beautifully staged property, Sarah O’Neil’s techniques offer a distinct advantage. Visit http://www.sarahoneilrealty.com/ to discover how her award-winning staging services can revolutionize your property sale experience.

Media Contact
Company Name: Sarah O’Neil Realty | Real Estate Agent in Bozeman MT
Contact Person: Sarah O’Neil
Email: Send Email
Phone: +1 406-579-9836
Address:1001 West Oak St Bldg. C, Suite 111
City: Bozeman
State: Montana 59715
Country: United States
Website: http://www.sarahoneilrealty.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Selling Agent in Bozeman, MT Revolutionizes Property Sales with Award-Winning Staging Techniques

Diabetic Retinopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight

“Diabetic Retinopathy Treatment Market”
Diabetic Retinopathy companies are Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences, OcuTerra Therapeutics, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd, LEO Pharma, AstraZeneca, Glenmark Pharmaceuticals, Sanofi, Abbott, Abbvie, Merck, Pfizer, and others.

(Albany, USA) DelveInsight’s “Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Diabetic Retinopathy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Diabetic Retinopathy market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Diabetic Retinopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Diabetic Retinopathy market.

 

Request for a Free Sample Report @ Diabetic Retinopathy Market Forecast

 

Some facts of the Diabetic Retinopathy Market Report are:

  • According to DelveInsight, Diabetic Retinopathy market size is expected to grow at a decent CAGR by 2034.
  • Leading Diabetic Retinopathy companies working in the market are Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences, OcuTerra Therapeutics, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd, LEO Pharma, AstraZeneca, Glenmark Pharmaceuticals, Sanofi, Abbott, Abbvie, Merck, Pfizer, and others.
  • Key Diabetic Retinopathy Therapies expected to launch in the market are BAY 1101042, OPT-302, RGX 314, Runcaciguat, OTT166, others.
  • The total Diabetic Retinopathy prevalent cases in the 7MM were 12,585,769 in 2021.
  • OTT-166 is a novel small molecule selective integrin inhibitor that OcuTerra has purpose-engineered to have the required physiochemical characteristics to be able to reach the retina from eye drop application. Phase 1b clinical trials of OTT-166 eye drops have demonstrated safety, tolerability, and clear clinical evidence of biological activity. OcuTerra is currently studying the safety, efficacy, and optimal dosing regimen of OTT166 through the Phase II DR: EAM (Diabetic Retinopathy: Early Active Management) study in patients with moderately-severe to severe non-proliferative and mild proliferative diabetic retinopathy.
  • RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDE, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314.

 

Diabetic Retinopathy Overview

Diabetic retinopathy is a diabetes-related eye disease characterized by damage to the blood vessels in the retina, leading to vision loss and blindness; it is caused by prolonged exposure to high blood sugar levels, resulting in weak, leaky, and blocked vessels, and can progress from non-proliferative retinopathy to proliferative retinopathy with abnormal blood vessel growth; symptoms include blurred vision, color vision impairment, and floaters; diagnosis involves comprehensive eye examinations, retinal examinations, and imaging tests like OCT and fluorescein angiography; treatment options include blood sugar control, laser photocoagulation, intravitreal injections, vitrectomy, and regular eye exams to manage and slow down the disease’s progression.

 

Learn more about Diabetic Retinopathy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/diabetic-retinopathy-market

 

Diabetic Retinopathy Market 

The Diabetic Retinopathy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Diabetic Retinopathy market trends by analyzing the impact of current Diabetic Retinopathy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Diabetic Retinopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Diabetic Retinopathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Diabetic Retinopathy market in 7MM is expected to witness a major change in the study period 2020-2034.

 

Diabetic Retinopathy Epidemiology  

The Diabetic Retinopathy epidemiology section provides insights into the historical and current Diabetic Retinopathy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Diabetic Retinopathy market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Diabetic Retinopathy Epidemiology @ Diabetic Retinopathy Prevalence

 

Diabetic Retinopathy Drugs Uptake

This section focuses on the uptake rate of the potential Diabetic Retinopathy drugs recently launched in the Diabetic Retinopathy market or expected to be launched in 2020-2034. The analysis covers the Diabetic Retinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Diabetic Retinopathy Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Diabetic Retinopathy market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Diabetic Retinopathy Pipeline Development Activities

The Diabetic Retinopathy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Diabetic Retinopathy key players involved in developing targeted therapeutics.

  • KSI-301: Kodiak Sciences
  • Brolucizumab: Novartis
  • RGX 314: Regenxbio Inc.
  • OTT-166: OcuTerra Therapeutics
  • OTX-TKI: Ocular Therapeutix
  • And others.

 

Request for a sample report to understand more about the Diabetic Retinopathy pipeline development activities @ Diabetic Retinopathy Treatment Market

 

Diabetic Retinopathy Therapeutics Assessment

Major key companies are working proactively in the Diabetic Retinopathy Therapeutics market to develop novel therapies which will drive the Diabetic Retinopathy treatment markets in the upcoming years are Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Ocuphire Pharma, Eisai Co Ltd, Apexian Pharmaceuticals, Oculis, Bayer, Novartis Pharmaceuticals, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, Kubota Vision Inc., KalVista Pharmaceuticals Ltd, LEO Pharma, AstraZeneca, Glenmark Pharmaceuticals, Sanofi, Abbott, Abbvie, Merck, Pfizer, and others.

 

Learn more about the emerging Diabetic Retinopathy therapies & key companies @ Diabetic Retinopathy Clinical Trials

 

Diabetic Retinopathy Report Key Insights

1. Diabetic Retinopathy Patient Population

2. Diabetic Retinopathy Market Size and Trends

3. Key Cross Competition in the Diabetic Retinopathy Market

4. Diabetic Retinopathy Market Dynamics (Key Drivers and Barriers)

5. Diabetic Retinopathy Market Opportunities

6. Diabetic Retinopathy Therapeutic Approaches

7. Diabetic Retinopathy Pipeline Analysis

8. Diabetic Retinopathy Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Diabetic Retinopathy Market

 

Table of Contents 

1. Key Insights

2. Executive Summary

3. Diabetic Retinopathy Competitive Intelligence Analysis

4. Diabetic Retinopathy Market Overview at a Glance

5. Diabetic Retinopathy Disease Background and Overview

6. Diabetic Retinopathy Patient Journey

7. Diabetic Retinopathy Epidemiology and Patient Population

8. Diabetic Retinopathy Treatment Algorithm, Current Treatment, and Medical Practices

9. Diabetic Retinopathy Unmet Needs

10. Key Endpoints of Diabetic Retinopathy Treatment

11. Diabetic Retinopathy Marketed Products

12. Diabetic Retinopathy Emerging Therapies

13. Diabetic Retinopathy Seven Major Market Analysis

14. Attribute Analysis

15. Diabetic Retinopathy Market Outlook (7 major markets)

16. Diabetic Retinopathy Access and Reimbursement Overview

17. KOL Views on the Diabetic Retinopathy Market

18. Diabetic Retinopathy Market Drivers

19. Diabetic Retinopathy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Retinopathy Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight

Ewing Sarcoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Patient Pool, Prevalence and Companies DelveInsight

“Ewing Sarcoma Market”
Ewing Sarcoma Companies are Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others.

(New York, USA) DelveInsight’s “Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Ewing Sarcoma, historical and forecasted epidemiology as well as the Ewing Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Ewing Sarcoma market report provides current treatment practices, Ewing Sarcoma emerging drugs, Ewing Sarcoma market share of the individual therapies, current and forecasted epidemiology in 7MM covering the  United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan from 2020 to 2034. Ewing Sarcoma Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities.

 

Request for sample page @ Ewing Sarcoma Market Forecast

 

Key Takeaways from the Ewing Sarcoma Market Report

  • According to DelveInsight, Ewing Sarcoma market is expected to grow at a decent CAGR by 2034.
  • The total Ewing Sarcoma Market Size in the 7MM is approximately USD 30 million in 2023 and is projected to increase during the forecast period (2024–2034).
  • The leading Ewing Sarcoma Companies include Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others.
  • Promising Ewing Sarcoma Pipeline Therapies include Vigil EWS, Eribulin mesylate, Seclidemstat, SM-88, Lurbinectedin, CP-751,871, Abemaciclib, CLR 131, VAL-413, TP-1287, Nivolumab, Bempegaldesleukin, INBRX-109, and others
  • According to DelveInsight’s analysis, men are more frequently effected than women (with 3:2), in case of Ewing Sarcoma.
  • Additionally, more than 80% of Ewing’s sarcomais attributed to bone, often in femur, pelvis, ribsetc. Extra-osseous affects the soft tissues aroundthe bones, such as cartilage or muscle.
  • On November 12, 2024, Actuate Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to elraglusib, a novel glycogen synthase kinase-3 beta (GSK-3β) inhibitor, for the treatment of Ewing sarcoma (EWS).
  • On November 12, 2024, the FDA granted rare pediatric disease designation to elraglusib (9-ING-41), a novel GSK-3β inhibitor, as a potential treatment for patients with Ewing sarcoma.

 

Ewing Sarcoma Overview

Ewing sarcoma is a rare and aggressive cancer that primarily affects the bones or the soft tissues surrounding bones. It most commonly occurs in children, adolescents, and young adults, with peak incidence between ages 10 and 20. The most frequent sites of occurrence include long bones like the femur, pelvis, ribs, and scapula.

The exact cause of Ewing sarcoma is unknown, but it is associated with specific genetic changes, most commonly a translocation between the EWSR1 gene on chromosome 22 and the FLI1 gene on chromosome 11. This fusion gene leads to uncontrolled cell growth.

Symptoms include localized pain and swelling, often worse at night, and can be accompanied by fever, fatigue, and unintentional weight loss. In advanced stages, the cancer may spread to other parts of the body, such as the lungs, bone marrow, or other bones. Diagnosis involves imaging studies (X-ray, MRI, or CT scans), biopsy for histological examination, and genetic testing to confirm the diagnosis.

Treatment typically combines chemotherapy, surgery, and/or radiation therapy. Multimodal therapy aims to eradicate the primary tumor and any metastases. While advancements in treatment have improved survival rates, early diagnosis and comprehensive care are critical to achieving favorable outcomes in Ewing sarcoma.

 

To know more about Ewing’s sarcoma treatment, visit @ Ewing Sarcoma Treatment Market

 

Recent Developmental Activities in the Ewing Sarcoma Treatment Landscape

  • Vigil (Gradalis) is a fully personalized cellular immunotherapy being examined for the treatment of advanced cancers with major focus on recurrent or refractory Ewing’s sarcoma. Vigil combines genetic engineering with immuno-oncology to stimulate an immune response against cancer cells. The cells from the tumor are genetically modified in two ways. First, the cells are modified to inhibit the production of furin protein that makes it difficult for the immune system to detect cancer cells. Second, cells are modified to produce granulocyte macrophage colony-stimulating factor (GM-CSF). Phase I study revealed clinical benefit with a median survival of two years. While the median OS of patients in the Phase II study, treated with the combination of Vigil, Irinotecan, and Temozolomide was not met; however, favorable eventfree survival was observed. It is currently under phase III trial and the estimated completion date of this study is December 2022.
  • Eribulin mesylate (Eisai) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action and inhibit the growth phase of microtubule dynamics, with increased vascular perfusion and permeability in tumor cores. It is currently under phase II trial for Ewing Sarcoma. In pre-clinical studies, eribulin showed broad-spectrum cytotoxicity and had low IC50 values when tested using a large panel of cancer cell lines. This investigational molecule has completed Phase II trial an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) in January 2022.
  • SM-88 (Tyme) is a novel, oral, investigational agent evaluated as maintenance therapy in combination with methoxsalen, phenytoin. SM88 is an exclusive dysfunctional tyrosine derivative and is the backbone of SM-88 used with MPS. It is designed to be absorbed by the cancer cell as if it were a functional tyrosine, but after uptake it interrupts the processes of protein synthesis, with key targeting of mucin 1. it is currently under phase II trial for Ewing Sarcoma and the estimated completion of this study is by 2022.
  • Seclidemstat (Salarius Pharmaceuticals) is a small molecule designed to inhibit lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme regulating gene expression. LSD1 has been implicated in various types of cancer, with higher levels of LSD1 associated with poor patient prognosis. Seclidemstat (SP 2577) has been shown to inhibit LSD1’s demethylation and scaffolding properties and has demonstrated potent therapeutic activity in preclinical models of Ewing sarcoma, a rare pediatric/adolescent bone cancer. It is currently under Phase I clinical trial and the expected completion date of this study in September 2023.

 

Ewing Sarcoma Epidemiology Segmentation in the 7MM

  • Ewing Sarcoma Incident Cases
  • Ewing Sarcoma Subtype-specific Cases
  • Ewing Sarcoma Age-Specific Cases
  • Ewing Sarcoma Gender-Specific Cases

 

Download the report to understand which factors are driving Ewing Sarcoma epidemiology trends @ Ewing Sarcoma Prevalence

 

Ewing Sarcoma Market Insights

The overall improvement in outcome of ES has been made through the tremendous efforts of researcher, clinicians all over the world, better liaison between all the stakeholders of treating team, and collaborative international research in a huge number of cases. The main challenge now remains in preventing recurrence, preventing drug resistance, reducing therapy related long-term toxicities and improving outcome in those with metastatic and relapsed/recurrent disease.

 

Ewing’s Sarcoma Market Dynamics

The dynamics of Ewing Sarcoma market is expected to change due to the improvement in the diagnosis, incremental healthcare expenditure across the world and expected launch of emerging therapies during the forecast period of 2022─2034. Companies all over the globe are persistently working towards the development of new treatment therapies and some of the key players at the global level are Tyme, Gradalis, Oncurious, Eisai, and others.

 

Ewing Sarcoma Market Landscape

Anticipated launch of therapies such as Vigil, Eribulin mesylate is expected to fuel the growth of the market during the forecast period, i.e., 2022–2034. Widespread research and developmental activities of pharmaceutical companies, along with rising incidence will further fuel the growth of the market.

 

Learn more about the FDA-approved drugs for Ewing Sarcoma @ Ewing Sarcoma Therapies and Medication

 

Scope of the Ewing Sarcoma Market Report

  • Coverage- 7MM
  • Ewing Sarcoma Companies- Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others
  • Ewing Sarcoma Pipeline Therapies- Vigil EWS, Eribulin mesylate, Seclidemstat, SM-88, Lurbinectedin, CP-751,871, Abemaciclib, CLR 131, VAL-413, TP-1287, Nivolumab, Bempegaldesleukin, INBRX-109, and others
  • Ewing Sarcoma Market Dynamics: Ewing Sarcoma Market Drivers and Barriers
  • Ewing Sarcoma Market Access and Reimbursement, Unmet Needs, and Emerging Drugs

 

Discover more about Ewing Sarcoma Drugs in development @ Ewing Sarcoma Clinical Trials

 

Table of Content

  1. Key Insights
  2. Executive Summary of Ewing Sarcoma
  3. Competitive Intelligence Analysis for Ewing Sarcoma
  4. Ewing Sarcoma: Market Overview at a Glance
  5. Ewing Sarcoma: Disease Background and Overview
  6. Ewing Sarcoma Patient Journey
  7. Ewing Sarcoma Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Ewing Sarcoma Unmet Needs
  10. Key Endpoints of Ewing Sarcoma Treatment
  11. Ewing Sarcoma Marketed Products
  12. Ewing Sarcoma Emerging Therapies
  13. Ewing Sarcoma: Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Ewing Sarcoma Market Outlook
  16. Access and Reimbursement Overview of Ewing Sarcoma
  17. KOL Views
  18. Ewing Sarcoma Market Drivers
  19. Ewing Sarcoma Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ewing Sarcoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Patient Pool, Prevalence and Companies DelveInsight

Autosomal Dominant Polycystic Kidney Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight

“Autosomal Dominant Polycystic Kidney Disease Treatment Market”
Autosomal Dominant Polycystic Kidney Disease Companies are Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, Reata Pharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others.

(Albany, USA) DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Autosomal Dominant Polycystic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autosomal Dominant Polycystic Kidney Disease Market Forecast

 

Some of the key facts of the Autosomal Dominant Polycystic Kidney Disease Market Report: 

  • The Autosomal Dominant Polycystic Kidney Disease market size was valued approximately ~USD 1,476 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In 2023, the US market was valued at around USD 889.8 million. This figure is expected to shift with the introduction of emerging therapies throughout the forecast period (2024-2034).
  • In 2023, the combined market size of EU4 and the UK was approximately USD 7,395 million, representing nearly 39.4% of the total 7MM market.
  • In the EU4 and the UK, the UK had the largest autosomal dominant polycystic kidney disease market size at around USD 72.5 million, followed by France with approximately USD 65.6 million and Spain with USD 29.4 million. These figures are projected to shift by 2034.
  • In 2023, Japan represented about 26% of the total Autosomal Dominant Polycystic Kidney Disease market across the 7MM. These proportions are expected to shift by 2034.
  • According to DelveInsight’s analysis, the total diagnosed prevalent cases of autosomal dominant polycystic kidney disease in the 7MM were approximately 194,251 in 2023. This number is expected to change during the forecast period from 2024 to 2034.
  • In 2023, the US reported approximately 144,697 diagnosed prevalent cases of autosomal dominant polycystic kidney disease.
  • In 2023, the UK reported the highest number of autosomal dominant polycystic kidney disease diagnosed prevalent cases among the EU4 and the UK, with approximately 68,138 cases, followed by France with 61,676 cases. Italy had the lowest, with nearly 16,476 cases.
  • Key Autosomal Dominant Polycystic Kidney Disease Companies: Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others
  • Key Autosomal Dominant Polycystic Kidney Disease Therapies: JYNARQUE/ JINARC/SAMSCA (tolvaptan), VX-407, Bosutinib, Tolvaptan, Lixivaptan, Everolimus, OPC-41061, Rapamune, XRx-008, Bardoxolonemethyl, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and others
  • The ADPKD epidemiology based on mutation-specific cases analyzed that the mutation-specific distribution of the disease suggests a higher prevalence of ADPKD due to mutation in PKD1 gene than in PKD2 gene
  • The Autosomal Dominant Polycystic Kidney Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Autosomal Dominant Polycystic Kidney Disease pipeline products will significantly revolutionize the Autosomal Dominant Polycystic Kidney Disease market dynamics.

 

Autosomal Dominant Polycystic Kidney Disease Overview

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. It is caused by mutations in either the PKD1 or PKD2 genes, which disrupt normal kidney cell function. This leads to progressive kidney enlargement, structural damage, and eventual loss of kidney function.

Symptoms typically appear in adulthood, although some individuals remain asymptomatic for years. Common signs include high blood pressure, back or flank pain, blood in the urine (hematuria), recurrent urinary tract infections, and kidney stones. Over time, the disease can progress to chronic kidney disease (CKD) and end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation.

ADPKD can also cause extrarenal complications, including liver cysts, aneurysms in brain blood vessels, heart valve abnormalities, and hernias. Diagnosis is often confirmed through imaging studies like ultrasound, CT, or MRI, and genetic testing may be utilized for high-risk individuals.

Treatment focuses on managing symptoms and slowing disease progression. Blood pressure control, dietary modifications, and pain management are essential. Medications such as tolvaptan may be prescribed to delay kidney function decline. Regular monitoring and early intervention are crucial to improving quality of life for individuals with ADPKD.

 

Get a Free sample for the Autosomal Dominant Polycystic Kidney Disease Market Forecast, Size & Share Analysis Report: ADPKD Market Dynamics

 

Autosomal Dominant Polycystic Kidney Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation:

The Autosomal Dominant Polycystic Kidney Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Autosomal Dominant Polycystic Kidney Disease
  • Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease by severity
  • Gender-specific Prevalence of Autosomal Dominant Polycystic Kidney Disease
  • Diagnosed Cases of Episodic and Chronic Autosomal Dominant Polycystic Kidney Disease

 

Download the report to understand which factors are driving Autosomal Dominant Polycystic Kidney Disease epidemiology trends @ Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast

 

Autosomal Dominant Polycystic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autosomal Dominant Polycystic Kidney Disease market or expected to get launched during the study period. The analysis covers Autosomal Dominant Polycystic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Autosomal Dominant Polycystic Kidney Disease Therapies and Key Companies

  • JYNARQUE/ JINARC/SAMSCA (tolvaptan): Otsuka America Pharmaceuticals
  • VX-407: Vertex Pharmaceuticals
  • Bosutinib: Pfizer
  • Tolvaptan: Otsuka Pharma
  • Lixivaptan: Palladio Biosciences
  • Everolimus: Novartis Pharma
  • OPC-41061: Otsuka Pharma
  • Rapamune: Pfizer
  • XRx-008: XORTX Therapeutic
  • Bardoxolonemethyl: ReataPharmaceuticals/ Kyowa Kirin
  • Tesevatinib/KD019: Sanofi
  • GLPG2737: Galapagos NV
  • JNJ-0237/AT-20494: Janssen Pharmaceuticals
  • RGLS8429: Regulus Therapeutics

 

Discover more about therapies set to grab major Autosomal Dominant Polycystic Kidney Disease market share @ Autosomal Dominant Polycystic Kidney Disease Treatment Landscape

 

Autosomal Dominant Polycystic Kidney Disease Market Drivers

  • Technological advances in diagnostic procedures due to an increasing focus on early diagnosis has reduced undiagnosed cases, thus persistent rising cases of diagnosed ADPKD offer opportunities to companies to launch new therapies in the market.
  • Advances are being made in unravelling the genetic origins of ADPKD, in non-invasive monitoring and in predicting disease progression that will help in better disease management

 

Autosomal Dominant Polycystic Kidney Disease Market Opportunities

  • Pre-symptomatic diagnosis and their application in the care and management of individuals at risk for ADPKD.
  • Identification of biomarkers for early detection of ADPKD patients at high risk for progression will help better manage ADPKD patients and prevent their progression.

 

Scope of the Autosomal Dominant Polycystic Kidney Disease Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Autosomal Dominant Polycystic Kidney Disease Companies: Otsuka America Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others
  • Key Autosomal Dominant Polycystic Kidney Disease Therapies: JYNARQUE/ JINARC/SAMSCA (tolvaptan), VX-407, Bosutinib, Tolvaptan, Lixivaptan, Everolimus, OPC-41061, Rapamune, XRx-008, Bardoxolonemethyl, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and others
  • Autosomal Dominant Polycystic Kidney Disease Therapeutic Assessment: Autosomal Dominant Polycystic Kidney Disease current marketed and Autosomal Dominant Polycystic Kidney Disease emerging therapies
  • Autosomal Dominant Polycystic Kidney Disease Market Dynamics: Autosomal Dominant Polycystic Kidney Disease market drivers and Autosomal Dominant Polycystic Kidney Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Autosomal Dominant Polycystic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement 

 

To know more about Autosomal Dominant Polycystic Kidney Disease companies working in the treatment market, visit @ Autosomal Dominant Polycystic Kidney Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Autosomal Dominant Polycystic Kidney Disease Market Report Introduction

2. Executive Summary for Autosomal Dominant Polycystic Kidney Disease

3. SWOT analysis of Autosomal Dominant Polycystic Kidney Disease

4. Autosomal Dominant Polycystic Kidney Disease Patient Share (%) Overview at a Glance

5. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance

6. Autosomal Dominant Polycystic Kidney Disease Disease Background and Overview

7. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Autosomal Dominant Polycystic Kidney Disease 

9. Autosomal Dominant Polycystic Kidney Disease Current Treatment and Medical Practices

10. Autosomal Dominant Polycystic Kidney Disease Unmet Needs

11. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies

12. Autosomal Dominant Polycystic Kidney Disease Market Outlook

13. Country-Wise Autosomal Dominant Polycystic Kidney Disease Market Analysis (2020–2034)

14. Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement of Therapies

15. Autosomal Dominant Polycystic Kidney Disease Market Drivers

16. Autosomal Dominant Polycystic Kidney Disease Market Barriers

17.  Autosomal Dominant Polycystic Kidney Disease Appendix

18. Autosomal Dominant Polycystic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Autosomal Dominant Polycystic Kidney Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight

Atopic Dermatitis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight

“Atopic Dermatitis Treatment Market”
Atopic Dermatitis Companies are Sanofi/Regeneron Pharmaceuticals, RAPT Therapeutics, Pfizer, Japan Tobacco, and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, AOBiome Therapeutics, Kymab, Qurient, Arcutis Biotherapeutics, Cara Therapeutics, Vanda Pharmaceuticals, and others.

(Albany, USA) DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Atopic Dermatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atopic Dermatitis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Atopic Dermatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Atopic Dermatitis market.

 

Request for sample page @ Atopic Dermatitis Market Forecast

 

Key Takeaways from the Atopic Dermatitis Market Report

  • According to DelveInsight, Atopic Dermatitis market size is expected to grow at a decent CAGR by 2034.
  • In 2023, the total Atopic Dermatitis Market Size in 7MM was around USD 17 billion, which is expected to increase by 2034 during the study period (2020–2034) in the 7MM.
  • Leading Atopic Dermatitis Companies in the treatment market Sanofi/Regeneron Pharmaceuticals, RAPT Therapeutics, Pfizer, Japan Tobacco, and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, AOBiome Therapeutics, Kymab, Qurient, Arcutis Biotherapeutics, Cara Therapeutics, Vanda Pharmaceuticals, and others.
  • Promising Atopic Dermatitis Pipeline Therapies include Baricitinib, Dupilumab, Lebrikizumab, and others.
  • Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.
  • The total prevalent cases of Atopic Dermatitis in the United States were around 32,573,900 cases in 2022.
  • Approximately 60–70% of diagnosed Atopic dermatitis cases are mild, whereas ~30% are moderate-to-severe.
  • April 2024: Suzhou Zelgen Biopharmaceuticals Co.,Ltd- A Phase I/II Study Of The Efficacy,Safety and PharmacokineticsOf Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Atopic Dermatitis. This study includes a dose escalation part and a dose extension part.
  • April 2024: Pfizer- A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-07275315 AND PF-07264660 IN ADULT PARTICIPANTS WITH MODERATE-SEVERE ATOPIC DERMATITIS. The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.
  • April 2024: Eli Lilly and Company- An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab. The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.

 

Discover more about therapies set to grab major Atopic Dermatitis market share @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market

 

Atopic Dermatitis Overview

Atopic dermatitis, also known as eczema, is a chronic skin condition characterized by inflamed, itchy, and dry skin. It commonly affects children and may persist into adulthood. The exact cause is unknown, but it is believed to be a combination of genetic and environmental factors. Symptoms include red, patchy, and scaly skin that can become thickened or cracked. Treatment aims to relieve symptoms and prevent flare-ups, typically involving moisturizers, topical corticosteroids, and antihistamines. Lifestyle modifications, such as avoiding triggers and maintaining proper skin care, can also help manage the condition. Consultation with a healthcare professional is recommended for diagnosis and personalized treatment.

 

 Atopic Dermatitis Epidemiology Segmentation

  • Atopic Dermatitis Prevalent Population
  • Diagnosed Prevalent Population of Atopic Dermatitis
  • Severity-specific Distribution of Atopic Dermatitis in Adults
  • Severity-specific Distribution of Atopic Dermatitis in Pediatric Population
  • Gender-specific Distribution of Atopic Dermatitis in Adults
  • Chronic Pruritus Prevalence in Atopic Dermatitis in the adults

 

Download the report to understand which factors are driving Atopic Dermatitis epidemiology trends @ Atopic Dermatitis Market Dynamics

 

Atopic Dermatitis Emerging Drugs 

Rocatinlimab (KHK4083/AMG 451): Amgen/Kyowa Kirin

Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number of OX40-expressing pathogenic T cells responsible for driving systemic and local inflammatory responses. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with Atopic Dermatitis and are critical in the disease pathophysiology. The initial antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology. 

Amgen and Kyowa Kirin have recently begun recruiting participants for a comprehensive, global Phase III program (ROCKET program) to investigate the safety and efficacy of rocatinlimab in a heterogeneous moderate-to-severe AD population suffering from a high burden of disease.

 

Atopic Dermatitis Market Dynamics

Atopic Dermatitis market to expand because of the emergence of several novel mechanisms such as oral/topical JAK Inhibitors, PDE Inhibitors, IL-13 Inhibitors, leukotriene inhibitors, Kappa opioid receptor (KOR) agonist, NK-1 receptor antagonist, and others in the upcoming market of Atopic Dermatitis and pruritus in Atopic Dermatitis. Increased public awareness, improved access to health services, reimbursements, and financial support may boost the Atopic Dermatitis and pruritus in the market and improve the Atopic Dermatitis market accessibility of the emerging drugs.

 

To know more about Atopic Dermatitis Treatment options, visit @ Atopic Dermatitis Treatment Market

 

Atopic Dermatitis Pipeline Companies

The developing pipeline of Atopic Dermatitis holds budding key players such as lebrikizumab (Eli Lilly), nemolizumab/CD14152 (Galderma), difamilast (Otsuka Pharmaceuticals), and roflumilast (Arcutis Biotherapeutics). These emerging drugs, predicted to be launched during the forecast period, are likely to change the current market dynamics of disease treatment, thereby boosting the current Atopic Dermatitis market size. Following the late-stage products, a wide array of mid-stage or Phase II promising interventions are expected to be launched soon in the Atopic Dermatitis market, including B244 (AOBiome Therapeutics), etrasimod/APD334 (Arena Pharmaceuticals), FB825 (Oneness Biotech), DS107 (DS Biopharma), bermekimab (Janssen), KY1005 (Sanofi/Kymab), and Q301 (Zileuton) (Qurient).

 

Learn more about the Atopic Dermatitis Pipeline Therapies @ Atopic Dermatitis Clinical Trials and Advancements

 

Scope of the Atopic Dermatitis Pipeline Report

  • Coverage- 7MM
  • Atopic Dermatitis Companies- Sanofi (NYSE: SNY), Regeneron Pharmaceuticals (NYSE: REGN), Pfizer (NYSE: PFE), Japan Tobacco, Torii Pharmaceutical (NYSE: TRXPF), Eli Lilly and Company (NYSE: LLY), AbbVie (NYSE: ABBV), LEO Pharma, Incyte Corporation (NYSE: INCY), Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen (NYSE: JNJ), AOBiome Therapeutics, Kymab, Qurient (NYSE: KRX), Arcutis Biotherapeutics (NYSE: ARQT), Cara Therapeutics (NYSE: CARA), Vanda Pharmaceuticals (NYSE: VNDA), and others.
  • Atopic Dermatitis Pipeline Therapies include Baricitinib, Dupilumab, Lebrikizumab, and others.
  • Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market Drivers and Barriers

 

Table of Content

  1. Key Insights
  2. Atopic Dermatitis Report Introduction
  3. Atopic Dermatitis (AD) Market Overview at a Glance
  4. Epidemiology and Market Methodology
  5. Executive Summary
  6. Atopic Dermatitis Disease Background and Overview
  7. Atopic Dermatitis Epidemiology and Patient Population
  8. Atopic Dermatitis Patient Journey
  9. Key Endpoints in Atopic Dermatitis Clinical Trials
  10. Atopic Dermatitis Marketed Therapies
  11. Atopic Dermatitis Emerging Therapies
  12. Atopic Dermatitis (Atopic Dermatitis): The 7MM Analysis
  13. Atopic Dermatitis Market Access and Reimbursement
  14. Atopic Dermatitis KOL Views
  15. Atopic Dermatitis SWOT Analysis
  16. Atopic Dermatitis Unmet Needs
  17. Appendix
  18. DelveInsight Capabilities
  19. Disclaimer

 

About DelveInsight

 

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Dermatitis Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, and Companies DelveInsight

FreeCast Expands Spanish Language Offering with Romance Channel and Suspenso Channel

A partnership with Senseof.Media brings two quality channels to the company’s Mis Canales offering.

FreeCast is announcing a partnership with Senseof.Media, bringing two Spanish-language channels to the free service’s collection of hundreds of FAST channels. The Romance Channel and Suspenso Channel are now available to all FreeCast users at no additional cost, as part of the company’s Mis Canales Spanish language offering.

Two exciting new TV channels are now available, offering a carefully curated selection of films and TV series from top international broadcasters, catering to a wide range of genres. The Romance Channel brings an enchanting collection of love stories and romantic comedies, offering both films and TV series that celebrate LOVE. Meanwhile, the Suspenso Channel delivers thrilling dramas, crime stories, and suspense-filled series, perfect for fans of mystery and intrigue. These Spanish-language channels are designed to engage Hispanic viewers across the US, with a particular appeal to women, offering compelling entertainment that spans popular genres.

FreeCast’s Executive Vice President of Digital Content, Tracy West, discussed the expansion of Mis Canales. “The power of our platform is that we can deliver a customized TV experience that puts our customers in control. That allows us to cater to audiences, like Latinos, in a way that really isn’t possible with traditional TV or even other VOD and FAST platforms. The Romance Channel and Suspenso Channel strengthen our offering for Spanish-speakers and show the value of our service.” 

“We are immensely proud to bring the Romance Channel and Suspenso Channel, which already captivate over 8.5 million unique viewers monthly across more than 50 countries and four continents in four languages, to FreeCast’s platform. With 3,000 hours of premium international content, including romantic dramas, comedies, crime stories, and suspenseful thrillers in Latin American Spanish, this partnership marks an exciting milestone in making our beloved channels accessible to Hispanic audiences in the U.S. FreeCast’s innovative approach to content distribution is perfectly aligned with our mission to deliver diverse and engaging entertainment to viewers across the Americas,” said Michael Kovalchuk, the CEO of Senseof.Media Inc.

Media Contact
Company Name: FreeCast Inc.
Contact Person: Kevin Speedy
Email: Send Email
Phone: (407) 374-1607
Address:6901 TPC Drive Suite 200
City: Orlando
State: Florida
Country: United States
Website: https://freecast.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FreeCast Expands Spanish Language Offering with Romance Channel and Suspenso Channel